 |
 |
Penny Stock Fortunes -- January 2007 To see the PDF version, click here.
We are all aware that AIDS has devastated the lives of millions of men, women and children throughout the world. Since 1981, AIDS has killed more than 25 million people. Last year alone, HIV infected more than 4 million adults and children. And the impact stretches far beyond these grim numbers The AIDS death toll also has a tremendous social and economic impact in Africa. U.N. Secretary General Kofi Annan said between 1999 and 2000, more people died of AIDS in Africa than in all the bloody wars taking place on the continent. Many of these African nations that are most affected by AIDS are seeing their quality of life dip even lower. As AIDS continues to spread, life expectancies in some African countries have dropped dramatically. But there is hope. The impact of the disease has gotten so great that even the most callous leaders realize something must be done. And now, the search for a miracle to save these millions of AIDS patients from an early death has reached a critical stage. I believe the medical miracle an entire continent has been searching for is here. This miracle is a revolutionary HIV testing system that could help some of the biggest drug companies administer new, advanced treatments to AIDS patients around the world. It’s not science fiction. Rather, it is a test that can determine the exact pattern of each individual’s virus. This allows the use of amazing new treatments that would otherwise be virtually useless. But Pfizer and Merck don’t hold the keys to this test’s success. It’s an unknown, $220 million biotech that’s ready to change the world. Doctors and executives from most of these drug giants have persuaded their respective companies to quietly invest resources in these tests. Now it’s your turn to stake your claim before the rest of the world takes note… Ride This Medical Trend to Huge Gains in 2007 One trend called “personalized medicine” will change medicine. Major drug companies are using personalized tests to develop new and better medicine — medicine that will target diseases that are specific to individual patients. It’s only a matter of time before the entire medical world is catering to your specific ailments. This tiny company’s patented testing solutions enable doctors to tailor their treatments to the precise needs of each patient. In fact, this “next generation” of medical tests has proven to be 100% accurate. The best any of the less-advanced mainstream tests could get was a 65% accuracy rate. That’s why this $220 million company will soon emerge as a leader in personalized medicine. And it’s also why doctors around the world will trust this company’s tests to help them treat their patients. With the technology to make personalized medicine mainstream, this company will not be trading at $1.60 a share for too much longer. Right now, some of the biggest and most cutting-edge drug companies in the world are using sophisticated new tests. These tests help to better select patients for clinical trials for new HIV and cancer treatments. And soon, physicians across the globe will be using these same techniques to treat patients will all sorts of diseases. Not just HIV. The developer of these diagnostic tests isn’t Merck or Pfizer. Instead, it’s a small $220 million firm. This one small company has partnered with more than 60 pharmaceutical, biotech and research organizations. This includes almost every company with a significant HIV drug development program. The bottom line is that any company that wants to gain a foothold in HIV treatments needs this unknown company to survive. This drug company savior is Monogram Biosciences, Inc. (MGRM: NASDAQ). The company develops special testing products that are so accurate that the big pharmaceutical companies are using the technology to develop better treatments. It’s all part of the new personalized medicine trend. As technology improves, it is becoming possible for doctors and drug companies to diagnose exactly what strain of the disease patients have. From there, physicians can better treat their patients using very specific drugs. But it’s not just a simple HIV test that makes Monogram such an important company. Twenty years ago, all HIV-positive patients were treated the same and had short life expectancies. But now, treatments are getting far more advanced. We’re seeing those who suffer from the virus living longer lives. Unfortunately, with more advanced treatments comes a disease that has begun to mutate and become even more deadly. You see, different strains and mutations of HIV exist. That’s what makes viruses so deadly. They can adapt to work around the current treatments that are widely used today. This is why Monogram’s tests are important. This company’s unique tests tell physicians and drug companies what specific viruses a patient has in his body and how the viruses are spreading through his system. Once they have this information, doctors can prescribe specific drugs that help target the specific virus strains and block how the disease infects healthy cells. |
|
